Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities

NCT01197833 | Completed Phase 3 Results DMC

• 1 other identifier: VAP.VV017
• Study Type: interventional
• Target: 117
• Locations: 1 country
• Sites: 7

Brief Summary

Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and may cause discomfort. In this study, patients with varicose veins in the legs will be participating. The purpose of this research study is to evaluate the safety and effectiveness of two different doses of an investigational drug, Polidocanol Endovenous Microfoam (PEM) compared to vehicle (inactive solution) when used following an approved heat treatment in subjects with varicose veins.

Conditions

Great Saphenous Vein Incompetence; Visible Varicosities

Keywords

varicose veins; Great saphenous vein; varicosities

Outcome Measures

Primary Outcomes (2)

• Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score)

  The Independent Photography Review - Visible Varicose Veins (IPR-V3) instrument is a 5-point scale used to assess the appearance of a patient's visible varicose veins. At screening, the site clinician was instructed to review the appearance of the patient's varicose veins in the medial section of each leg (a 'live' assessment), then select an IPR-V3 score (i.e., none=0, mild, moderate, severe or very severe=4) that best represented the appearance of the patient's varicose veins. This assessment took into account the attributes caliber, dilatation, tortuosity, and extent and number of varicosities, and was used to determine patient eligibility. The site clinician used a set of reference photographs (2 example photographs for each score on the scale) to assist with assigning a score to the appearance of the patient's visible varicose veins.

  IPR-V3 measured at baseline and then at 8 weeks

• Absolute Change From Baseline in PA-V3 Score

  The Patient Self-assessment of Visible Varicose Veins (PA-V3) instrument is a 5-point scale used by patients to evaluate the appearance of their visible varicose veins. On this paper questionnaire, the instructions included a diagram of the medial view of a leg with the area between the ankle and the groin circled. The patient was instructed to choose 1 of 5 response options that best described the appearance of the visible varicose veins of the leg that was treated in the study. The patient was instructed not to consider the appearance of the leg outside the circled area or of any spider veins. Possible responses ranged from "Not at all noticeable" (a score of 0) to "Extremely noticeable" (a score of 4)

  PA-V3 measured at baseline and then at 8 weeks

Study Arms (3)

Endovenous ablation+polidocanol injectable microfoam 0.125%

EXPERIMENTAL

Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein

Drug: endovenous ablation+polidocanol injectable microfoam 0.125%

Endovenous ablation+polidocanol injectable micrfoam, 1.0%

EXPERIMENTAL

Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein

Drug: Endovenous ablation+polidocanol injectable microfoam 1.0%

endovenous ablation+vehicle (placebo)

ACTIVE COMPARATOR

endovenous ablation followed by injection of vehicle (placebo) to target vein

Drug: Endovenous ablation+polidocanol injectable foam 2.0%

Interventions

endovenous ablation+polidocanol injectable microfoam 0.125% DRUG

All components except API

Also known as: endovenous ablation followed by polidocanol endovenous microfoam 0.125% injection to target vein

Endovenous ablation+polidocanol injectable microfoam 0.125%

Endovenous ablation+polidocanol injectable microfoam 1.0% DRUG

endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%

Also known as: Endovenous ablation followed by injection of polidocanol injectable foam 1.0% to target vein

Endovenous ablation+polidocanol injectable micrfoam, 1.0%

Endovenous ablation+polidocanol injectable foam 2.0% DRUG

Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%

Also known as: Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%

endovenous ablation+vehicle (placebo)

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Incompetence of SFJ
• Patients who are candidates for ETA \[laser or radiofrequency ablation (RFA)\]
• Symptomatic varicose veins
• Visible varicose veins
• Ability to comprehend and sign an informed consent and complete study questionnaires in English

You may not qualify if:

• Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP Classification of Venous Disorders)
• Patients who have active ulceration on the leg to be treated (Clinical Finding C6, as assessed by CEAP Classification of Venous Disorders)
• Leg obesity impairing the ability to access the vein to be treated and/or to apply post-procedure compression bandaging and stockings
• Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion
• Deep venous reflux unless clinically insignificant in comparison to superficial reflux
• Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings
• Reduced mobility
• History of deep vein thrombosis, pulmonary embolism or stroke, including evidence of prior DVT on duplex ultrasound
• Major surgery, prolonged hospitalization or pregnancy within 3 months of screening
• Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)
• Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions
• Current alcohol or drug abuse
• Pregnant or lactating women
• Women of childbearing potential not using effective contraception

Sponsors & Collaborators

• Boston Scientific Corporation: lead

Study Sites (7)

Unknown Facility

Scottsdale, Arizona, 85255, United States

Location

Unknown Facility

Bradenton, Florida, 34209, United States

Location

Unknown Facility

Oak Brook, Illinois, 60523, United States

Location

Unknown Facility

North Tonawanda, New York, 14120, United States

Location

Unknown Facility

Stony Brook, New York, 11974, United States

Location

Unknown Facility

Charlotte, North Carolina, 28207, United States

Location

Unknown Facility

Kirkland, Washington, 98034, United States

Location

Related Publications (1)

• Vasquez M, Gasparis AP; Varithena(R) 017 Investigator Group. A multicenter, randomized, placebo-controlled trial of endovenous thermal ablation with or without polidocanol endovenous microfoam treatment in patients with great saphenous vein incompetence and visible varicosities. Phlebology. 2017 May;32(4):272-281. doi: 10.1177/0268355516637300. Epub 2016 Mar 7.

  PMID: 26957489 DERIVED

MeSH Terms

Conditions

Varicose Veins

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Results Point of Contact

• Title: David Wright MB FRCS
• Organization: BTG International Inc

david.wright@btgplc.com

610-278-1660

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 8, 2010
• First Posted: September 9, 2010
• Study Start: September 1, 2010
• Primary Completion: March 1, 2012
• Study Completion: December 1, 2012
• Last Updated: April 21, 2021
• Results First Posted: September 15, 2014

Record last verified: 2021-04

Locations

US (7)